The Global Diabetes Market: Therapeutics, Diagnostics and Complications

Diabetes is one of the largest therapeutic segments of global pharmaceutical sales and during the last 10 years it has grown by a compound average growth rate of nearly 20% from around US$4 billion in 1995 to over US$17 billion in 2005.  Overall, anti-diabetic drugs sales are expected to grow dramatically over the next five years to over US$22 billion in 2012 as the addressable patient population continues to increase and new, oral, injectable and pulmonary premium priced products enter the market to address high unmet clinical needs.

The Global Diabetes Market assesses the markets for diabetes therapeutics, as well as the markets for diagnostic products and those that treat diabetic complications. This new report from Arrowhead Publishers incorporates new clinical findings presented at the 2006 conference of the American Diabetes Association into our product outlooks and financial forecasts. This report also analyzes, clinically and financially, the leading products on the market, the major players, as well as the groundbreaking new products in clinical development. Financial forecasts are also provided for individual products as well as for product classes.

Key Features of This Report:

• A thorough global market breakdown of key products and players in the non-insulin, insulin, diagnostic and diabetic neuropathy areas
• Individual chapters outlining the drivers of and resistors on this growing market
• Clinical evaluations of products and product classes in both the insulin and non-insulin markets
• Financial forecasts through 2012 for products and product classes in the areas of insulin, non-insulin, alternative therapies and diabetic complications
• Thorough analysis of products in clinical development, including coverage of safety, efficacy, market potential and filing timelines
• 96 tables/figures illustrating scientific and market aspects of the global diabetes market

Who Should Buy This Report:

• Companies interested in understanding the wider opportunities and challenges in the markets for diabetes therapeutics, diagnostics and products for diabetic complications
• Pharma/biotech companies wishing to identify opportunities and threats to products in these markets in order to examine a variety of profit maximization strategies
• Companies interested in understanding the state of R&D in relation to insulin, non-insulin, diagnostics and diabetic complication products